PPG, Essilor in talks about Transitions Optical joint venture

Article

Discussions continue about what the future will hold for the Transitions Optical, the joint venture of Essilor International and PPG Industries.

 

Pittsburgh-PPG Industries Inc. continues discussions with Essilor International regarding the future of PPG’s and Essilor’s joint venture (JV), Transitions Optical. PPG is majority shareholder in Transitions Optical, holding a 51% interest in the JV companies. Essilor holds the remaining 49% interest and also is the largest customer of Transitions Optical.

PPG said it cannot predict the outcome of the discussions with Essilor regarding the future of Transitions Optical but believes that possible outcomes may include a modification of the current JV structure, a sale of all or a portion of PPG’s interests in Transitions Optical to Essilor, or a sale of all or a portion of Essilor’s interests in Transitions Optical to PPG.

PPG said it cannot predict the timing of the completion of its discussions with Essilor but expects that these talks are likely to continue over the next several months.

The two shareholders emphasized that their discussions will not impact the day-to-day operations of Transitions Optical. 

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Recent Videos
Melissa Tawa, OD, FAAO, provides insights to take glaucoma management from reactive to proactive in presentations given at CRU 2025 in Napa, California.
Rachelle Lin, OD, MS, FAAO, details her presentation on inherited retinal diseases at CRU 2025.
Setting the stage in LA: Neda Shamie, MD, on the 19th annual Controversies in Modern Eye Care meeting
Jennifer Li, MD, details a talk she gave alongside Melissa Barnett, OD, FAAO, FSLS, FBCLA, at CRU 2025 in Napa, California.
Deb Ristvedt, DO, details a handful of presentations on glaucoma she gave during CRU 2025 in Napa, California.
Cecelia Koetting, OD, FAAO, DipABO, weighs in on patient assessments, staining pattern insights, and diagnostic tips for patients who may have dry eye disease.
Melissa Barnett, OD, FAAO, FSLS, FBCLA, discusses keratoconus management, diagnosis, and other key insights at CRU 2025.
Cecelia Koetting, OD, FAAO, DipABO, details a talk she gave among optometrists and ophthalmologists at CRU 2025.
Alongside Rachelle Lin, OD, MS, FAAO; Nguyễn, MD, MSc, detailed what treatments are currently available for retinal vascular diseases, including neovascular age-related macular degeneration and diabetic retinopathy.
Dr Paul Karpecki discusses atropine formulation from Sydnexis following NDA acceptance by FDA
© 2025 MJH Life Sciences

All rights reserved.